Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of a Mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof

Combination of a Mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof

US Patent 11466023 · Granted Oct 11, 2022

Estimated economic value: $566,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Substituted piperidines as inhibitors of ubiquitin specific protease 72022
Pyrrole compounds, a process for their preparation and pharmaceutical2021
Substituted piperidines for the treatment of cancer2021
Isoindoline or isoquinoline compounds, a process for their preparation and pharm2021
Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical 2020
Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical 2020
Hydroxyester derivatives, a process for their preparation and pharmaceutical com2020
Pyrrole compounds, a process for their preparation and pharmaceutical compositio2020
Isoindoline or isoquinoline compounds, a process for their preparation and pharm2020
Indole and pyrrole compounds, a process for their preparation and pharmaceutical2020
(Hetero)aryl-substituted-piperidinyl derivatives, a process for their preparatio2020
Bicyclic derivatives, a process for their preparation and pharmaceutical composi2020